Risperdal lawsuits are still being filed decades after the drug’s 1993 approval because many of the people harmed by it were children who are only now old enough to sue on their own, and because legal doctrines in most states pause or extend filing deadlines when the injured party is a minor or when the manufacturer allegedly concealed the risks. The drug, an atypical antipsychotic made by Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson, has been linked to gynecomastia — abnormal breast tissue growth in males — at rates significantly higher than other drugs in its class. Over 13,000 lawsuits have been filed, and J&J has paid out billions in settlements and verdicts, yet new claims continue to surface.
Consider Austin Pledger, a young man from Alabama who was prescribed Risperdal as a child and developed size 46DD breasts. A Philadelphia jury awarded him $2.5 million in 2015 — more than two decades after the drug first hit the market. His case is far from unique. This article examines the legal mechanisms that keep the courthouse doors open, the scale of the verdicts and settlements involved, the role J&J’s marketing played in creating this crisis, and what families dealing with Risperdal-related injuries should understand about their options today.
Table of Contents
- Why Are Risperdal Lawsuits Still Being Filed So Many Years After the Drug Was Approved?
- How Risperdal’s Off-Label Marketing Created a Generation of Plaintiffs
- The Staggering Scale of Risperdal Verdicts and What They Signal
- What Families Should Know Before Pursuing a Risperdal Claim
- The Black Box Warning and What It Means for Dementia Patients
- The 2013 DOJ Settlement and Its Lasting Significance
- Where Risperdal Litigation Stands Now and What Comes Next
- Conclusion
- Frequently Asked Questions
Why Are Risperdal Lawsuits Still Being Filed So Many Years After the Drug Was Approved?
The simplest answer is that many of the victims were children, and children cannot file lawsuits. In most states, the statute of limitations does not begin to run until a minor reaches the age of majority, which is typically eighteen. A boy who was prescribed Risperdal off-label at age eight in 2005, for example, would not see his statute of limitations clock start ticking until 2015 at the earliest. Add a two- or three-year filing window on top of that, and you reach 2017 or 2018 before the deadline passes — a quarter century after the drug’s initial approval. Some of those children, now adults, are only recently learning that their condition has a name and a pharmaceutical cause. Beyond the tolling rules for minors, the discovery rule plays a critical role. Many states allow the statute of limitations to begin not when the drug was taken, but when the plaintiff discovered — or reasonably should have discovered — the connection between Risperdal and their injury.
A young man who underwent breast reduction surgery at fifteen might not have connected his gynecomastia to his medication until years later, particularly if his prescribing physician never mentioned the risk. Compared to a standard product liability case involving, say, a defective appliance where the harm and the cause are obvious at the same moment, pharmaceutical injury cases often involve long delays between exposure, injury, and awareness. That gap is precisely what the discovery rule was designed to address. There is also the matter of fraudulent concealment. Plaintiffs in Risperdal litigation have argued that J&J knew about the elevated gynecomastia risk and actively downplayed it in communications with doctors and patients. When a defendant conceals the very information a plaintiff would need to file a timely claim, courts in many jurisdictions will extend the filing deadline accordingly. this doctrine has kept cases alive that might otherwise have been dismissed on procedural grounds.
How Risperdal’s Off-Label Marketing Created a Generation of Plaintiffs
Johnson & Johnson did not simply wait for doctors to prescribe Risperdal within its approved indications. The company aggressively marketed the drug off-label to two populations it was never initially approved for: children and elderly patients with dementia-related psychosis. This was not a matter of a few rogue sales representatives. In November 2013, J&J agreed to pay $2.2 billion to resolve criminal and civil allegations with the U.S. Department of Justice — one of the largest healthcare fraud settlements in American history at the time. that figure included a criminal fine and forfeiture totaling $485 million and civil settlements with federal and state governments totaling $1.72 billion. Among the findings: J&J had paid kickbacks to physicians and to Omnicare, the largest pharmacy serving U.S. nursing homes, to promote Risperdal use in elderly patients.
The off-label marketing to children is what generated the bulk of the personal injury claims. Risperdal elevates prolactin levels more than other atypical antipsychotics, and elevated prolactin is directly linked to gynecomastia. Studies have shown gynecomastia rates in boys taking Risperdal ranging from approximately 2.3 percent to over 5 percent — a figure that might sound small in isolation but that represents thousands of affected individuals when applied to the enormous number of pediatric prescriptions written during the drug’s peak years. Many of these children were prescribed Risperdal for behavioral issues, ADHD-adjacent symptoms, or irritability, conditions for which alternative treatments existed. However, it is important to note that off-label prescribing itself is legal. Doctors are permitted to use their clinical judgment to prescribe FDA-approved drugs for unapproved uses. What is not legal is for a manufacturer to market a drug for those unapproved uses, and that is where J&J crossed the line. The distinction matters because individual physicians who prescribed Risperdal in good faith are generally not the targets of these lawsuits. The claims are directed at the company that created a market for the drug in populations where the risk-benefit calculation was never properly evaluated or disclosed.
The Staggering Scale of Risperdal Verdicts and What They Signal
The numbers in Risperdal litigation have been extraordinary, even by the standards of mass pharmaceutical litigation. The most dramatic example came in 2019, when a Philadelphia jury awarded $8 billion in punitive damages to Nicholas Murray, a plaintiff who alleged he developed breasts after taking the drug as a child. The trial judge later reduced that award to $6.8 million, and an appeals court subsequently reinstated a portion of the punitive damages. The original figure was never expected to stand — it exceeded J&J’s annual Risperdal revenue — but it sent an unmistakable message about how juries viewed the company’s conduct. Other verdicts have been substantial on their own terms. In 2016, a jury awarded $70 million to a Tennessee plaintiff, though that amount was also later reduced by the presiding judge.
These reductions are routine in cases where juries impose punitive damages that courts deem constitutionally excessive, but the pattern of enormous initial awards followed by judicial reductions tells its own story. Juries, when presented with evidence of what J&J knew and when, have repeatedly concluded that the company’s behavior warranted severe punishment. Judges, bound by due process precedent, have tempered those verdicts while still leaving significant awards in place. The Philadelphia Court of Common Pleas has been the central venue for Risperdal litigation, with the majority of the 13,000-plus cases consolidated there. Philadelphia’s courts have developed specialized experience with these claims, and the city’s plaintiff-friendly reputation has made it a preferred filing location. For families considering whether to pursue a claim, the track record of verdicts in this jurisdiction offers a concrete sense of how these cases have fared at trial, though every case turns on its own facts.
What Families Should Know Before Pursuing a Risperdal Claim
The first practical question for anyone considering a Risperdal lawsuit is whether the statute of limitations has run. This is not a question with a single answer because it depends on the state where the claim is filed, the age of the plaintiff, when the injury was discovered, and whether fraudulent concealment can be demonstrated. An adult who took Risperdal and developed gynecomastia ten years ago in a state with a two-year statute of limitations may be out of time — unless the discovery rule or concealment arguments apply. A young person who just turned eighteen and was prescribed the drug as a child almost certainly still has time. Consulting an attorney who specializes in pharmaceutical litigation is essential, and most offer free initial consultations. The second question is the nature and severity of the injury. The strongest Risperdal cases have involved boys and young men who developed significant breast tissue requiring surgical correction, typically mastectomy.
The physical, emotional, and psychological toll of gynecomastia in adolescent males is well-documented, and juries have shown clear sympathy for these plaintiffs. Cases involving other side effects, such as metabolic problems, weight gain, or movement disorders, have generally been less prominent in the litigation, though they are not without merit. The tradeoff for plaintiffs is straightforward: cases with documented gynecomastia and a clear prescribing history have the strongest track record, while cases involving less visible or less well-established injuries face a harder evidentiary road. Medical records are the backbone of any Risperdal claim. Plaintiffs need documentation showing they were prescribed risperidone (or brand-name Risperdal), the dates and duration of use, and medical evidence of the resulting injury. Gaps in records do not necessarily kill a case, but they make it harder. If a family is even considering a claim, preserving and gathering medical documentation should be the first step.
The Black Box Warning and What It Means for Dementia Patients
For readers of a dementia care website, one aspect of the Risperdal story demands particular attention. The drug carries an FDA black box warning — the most serious type of safety warning — regarding increased mortality risk in elderly patients with dementia-related psychosis. This warning was added after studies showed that atypical antipsychotics, including Risperdal, were associated with a roughly 1.6- to 1.7-fold increase in death rates among elderly dementia patients compared to placebo. The causes of death were varied, including heart-related events and infections, but the statistical signal was clear enough for the FDA to act. Despite this warning, antipsychotics including risperidone continue to be prescribed in nursing homes and memory care facilities for managing agitation, aggression, and psychotic symptoms in dementia patients.
The reality is that there are few effective pharmacological alternatives for severe behavioral symptoms, and caregivers and facilities sometimes face situations where a patient poses a danger to themselves or others. However, the black box warning means that any such use should involve careful informed consent, ongoing monitoring, and a clear understanding that the drug is being used off-label for a population in which it carries known, elevated risks. Families of dementia patients should ask direct questions about why an antipsychotic is being prescribed, what alternatives were considered, and what monitoring protocols are in place. The legal landscape for elderly dementia patients harmed by Risperdal is less developed than the gynecomastia litigation, in part because the injuries — accelerated decline, cardiovascular events, death — are harder to attribute specifically to the drug in a population already facing serious health challenges. That does not mean such claims are impossible, but families should understand that the evidentiary burden is different and often heavier.
The 2013 DOJ Settlement and Its Lasting Significance
The $2.2 billion settlement between J&J and the Department of Justice in 2013 stands as one of the defining moments in Risperdal’s legal history. The settlement resolved allegations that J&J marketed Risperdal for use in elderly dementia patients and children — populations for which it lacked FDA approval — and that the company paid kickbacks to the nursing home pharmacy Omnicare and to individual physicians to increase prescriptions. The criminal component included a guilty plea by Janssen to a misbranding charge, acknowledging that the company had introduced a misbranded drug into interstate commerce.
What the DOJ settlement did not do was compensate individual patients. The billions went to federal and state governments, not to the people who developed gynecomastia or suffered other adverse effects. That is why the parallel track of personal injury litigation has continued long after the government’s case was resolved. For individual plaintiffs, the DOJ findings have served as powerful evidence — a federal admission, effectively, that J&J’s marketing practices were illegal and harmful.
Where Risperdal Litigation Stands Now and What Comes Next
The wave of Risperdal lawsuits has crested but not ended. The bulk of the Philadelphia cases have been resolved through settlements or trials, but new claims continue to arrive as former pediatric patients reach adulthood and as awareness of the drug’s risks spreads. Risperdal went generic in 2008 as risperidone, and generic versions are still widely prescribed, meaning the population of potential plaintiffs is not static.
Any patient currently taking risperidone who develops gynecomastia or other serious side effects could, in theory, pursue a claim, though the legal theories may differ when a generic manufacturer rather than J&J is the defendant. Looking ahead, the Risperdal litigation has become a case study in how pharmaceutical companies can face legal consequences that span generations. The combination of pediatric plaintiffs, tolling rules, discovery doctrines, and concealment allegations has kept this litigation alive far longer than J&J likely anticipated when it first began marketing the drug in the early 1990s. For families affected by Risperdal, the message is that it may not be too late to explore legal options — but the window will not stay open forever, and the specific facts of each case matter enormously.
Conclusion
Risperdal lawsuits persist decades after the drug’s approval because the legal system has built-in mechanisms to protect people who were too young to act on their own behalf or who could not reasonably have known what caused their injuries. Johnson & Johnson’s $2.2 billion DOJ settlement, billions more in personal injury verdicts and settlements, and the sheer volume of over 13,000 filed cases reflect the scale of harm caused by aggressive off-label marketing of a drug with known and serious side effects. The gynecomastia cases have dominated the litigation, but the drug’s black box warning for elderly dementia patients is a reminder that the risks extend across age groups.
For anyone who took Risperdal or risperidone and experienced adverse effects — or for families whose loved ones in dementia care were prescribed the drug — understanding the legal timeline is critical. Statutes of limitations vary by state, and the discovery rule and tolling provisions that have kept cases alive will not apply indefinitely. Gathering medical records, consulting a pharmaceutical litigation attorney, and acting sooner rather than later are the most important practical steps. The courts have shown a willingness to hold J&J accountable, but only for plaintiffs who come through the door in time.
Frequently Asked Questions
Is it too late to file a Risperdal lawsuit?
It depends on your state’s statute of limitations, when you discovered the connection between Risperdal and your injury, and whether you were a minor when you took the drug. Many former pediatric patients still have time to file, but deadlines vary. An attorney specializing in pharmaceutical litigation can evaluate your specific situation.
What is gynecomastia, and how is it connected to Risperdal?
Gynecomastia is the development of abnormal breast tissue in males. Risperdal elevates prolactin levels more than other atypical antipsychotics, and elevated prolactin can trigger breast tissue growth. Studies have found gynecomastia rates in boys taking Risperdal ranging from roughly 2.3 percent to over 5 percent, significantly higher than rates associated with competing medications.
Did J&J admit wrongdoing in the Risperdal cases?
In the 2013 DOJ settlement, Janssen Pharmaceuticals pleaded guilty to a federal misbranding charge. The $2.2 billion settlement resolved allegations of illegal off-label marketing and kickbacks. However, in individual personal injury cases, J&J has generally contested liability even as juries have repeatedly found against the company.
Is Risperdal still prescribed today?
Yes. Risperdal went generic in 2008 as risperidone, and both branded and generic versions remain available by prescription. It is FDA-approved for schizophrenia, bipolar disorder, and irritability associated with autism. Off-label use continues in other contexts, including for elderly dementia patients, despite the black box warning about increased mortality risk in that population.
Can families of elderly dementia patients who were given Risperdal file lawsuits?
Potentially, though the legal landscape is more challenging than in the gynecomastia cases. The difficulty lies in establishing that Risperdal, rather than the underlying dementia or other health conditions, caused the specific harm. Families who believe a loved one was harmed should consult an attorney and gather all prescribing records and medical documentation.
How much compensation have Risperdal plaintiffs received?
Verdicts have ranged widely. Notable examples include a $2.5 million award in 2015, a $70 million verdict in 2016 that was later reduced, and an $8 billion punitive damages award in 2019 that was reduced to $6.8 million by the trial judge before an appeals court reinstated a portion. Settlement amounts in resolved cases are typically confidential.
